Literature DB >> 34497

Contribution of 4-hydroxy-alprenolol to adrenergic beta receptor blockade of alprenolol.

P Collste, K O Borg, H Aström, C von Bahr.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 34497     DOI: 10.1002/cpt1979254416

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  11 in total

1.  Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.

Authors:  P Seideman; K O Borg; K Haglund; C Von Bahr
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

2.  The relationship between serum concentrations and central nervous system actions of metoprolol.

Authors:  F M Gengo; J C Ermer; C Carey; G C Kalonaros; W B McHugh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

3.  Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.

Authors:  R L Smith
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Drug metabolite concentration-time profiles: influence of route of drug administration.

Authors:  J B Houston; G Taylor
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

5.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

Review 6.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

Review 7.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 8.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

9.  Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.

Authors:  R J Francis; P B East; J Larman
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.